dbGaP Study Accession: phs002522

NIH Institute/Center: NHLBI

RADx Data Program: RADx-rad

DOI: 10.60773/vbbc-kt11

Release Date: 09/04/2024

Updated Date: 11/15/2021

Study Description: This project involved the design, fabrication, and proof-of-concept testing of a novel MOF-SCENT system (Metal-Organic Frameworks for Screening COVID-19 by Electronic-Nose Technology) that features the following advantages: (1) Highly selective and sensitive detection of a variety of VOCs; (2) fast response and recovery time; (3) portable, low-cost, robust, easy-to-use, and deployable in any clinical, community, and everyday setting. The accurate, sensitive, low-cost, robust, and portable MOF-SCENT system provides a realistic approach to dramatically increase testing capacity for COVID-19 because it can be rapidly integrated into and adopted by the public and healthcare systems by deploying a large number of such systems at central facilities (e.g., airports, shopping malls), point-of-care sites (e.g., hospitals, pharmacies, urgent care centers), and workplaces and even homes. The manufacturing of the MOF-SCENT system can be easily scaled to >50,000 units because the simple design can be fabricated out of stainless steel in common machine shops and the MOF material is commercially available or can be synthesized in organic synthesis laboratories. The detector of the MOF-SCENT system could be manufactured based on existing portable vector network analyzer (VNA) interrogators (new VNA technology called MN7021A RF Sensor, Keysight Technologies, Santa Rosa, CA). Commercially-available VNAs would be stripped down to increase production output and reduce costs (Keysight Technologies can head up the effort to mass-produce the interrogators). Capital costs for the production ramp-up of large numbers of MOF-SCENT systems are minimal because existing machine shops and Keysight Technologies' electronic assembly infrastructure would be used. Installation of the MOF-SCENT system at homes, grocery stores, pharmacies, and medical clinics can significantly increase daily accessibility to on-demand accurate testing and thereby mitigate the second wave of infections of SARS-CoV-2. Keysight Technologies is the world's largest test and measurement manufacturer, with a well-established supply chain, superior logistics and technical support infrastructure, and a commitment to quality control.

Principal Investigator: Huang, Jie

Has Data Files: No

Study Domain: Novel Biosensing and VOC; Medical Device/Tool Development; Virological Testing; Self-Testing (At-Home or OTC); Point-of-Care (POC) Testing

Data Collection Method: Unspecified COVID Testing Device

Keywords: Proof-of-Concept; MOF-SCENT System; Near Patient Testing

Study Design: Device Validation Study

Multi-Center Study: FALSE

Data Types: Immunological; Other

Data Types, Other: Time Transient Sensor Data

Study Start Date: 12/21/2020

Study End Date: 12/30/2023

Species: Non-Human Data

Estimated Cohort Size: 20

Study Population Focus: Adults

Acknowledgement Statement: This study was supported through funding, 3U01HL152410-04S1, for the National Heart Lung and Blood Institute (NHLBI) as part of the RADx-rad program. Approved users should acknowledge the provision of data access by dbGaP for accession phs002522.v1.p1, and the NIH RADx Data Hub. Approved users should also acknowledge the specific version(s) of the dataset(s) obtained from the NIH RADx Data Hub.

Funding Opportunity Announcement (FOA) Number: RFA-OD-19-014

NIH Grant or Contract Number(s): 3U01HL152410-04S1

Consent/Data Use Limitations: General Research Use